Tailored CML Treatment in Indonesia, Let’s See More

Authors

  • Shinta Oktya Wardhani Haematology-Oncology Medical, Faculty of Medicine, Universitas Brawijaya, Malang

DOI:

https://doi.org/10.21776/ub.crjim.2023.004.02.01

Keywords:

CML, CML Treatment, Indonesian

References

Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R et al. High rates of durable response are achieved with imatinib after treatment with interferon  plus cytarabine : results fron the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 2009 Dec; 94(12): 1669–1675.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al. Long-term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, N Engl J Med 2017; 376:917-927.

Ciftciler R and Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. 2021. 25 : 7787-7798.

Oehler VG. First -generation vs second-generation tyrosine kinase inhibitors : which is best at diagnosis of chronic phase chronic myeloid leukemia? Haematologi 2020: 228 – 236.

Wijaya I, Damara FA, Roesli RMA, Marsaman LR and Bashari MH. Prognostic Implications of SOKAL, Hasford and EUTOS scores on Complete Hematologic and Early Molecular Responses in Newly Diagnosed Chronic Myeloid Leukemia Patients : A Prospective Cohorty Study. Sys Rev Pharm. 2021; 12(1) : 987-992.

Viera-Mion AL, Pereira NF, Funke VAM, Pasquini R. Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia. Rev Bras Hematol Hemoter. 2017. 39(3) : 210–215.

Bintoro SUY, Amrita PNA, Joewarini E, Suryohusodo P, Soebandiri S. Bcr-Abl tyrosine kinase domain mutation combinations affects imatinib resistance in chronic phase chronic myelogenous leukemia. The New Armenian Medical Journal. 2019. 13(4) : p53-58.

Reksodiputro AH, Tadjoedin H, Rinaldi I, Witarto AB. Preliminary Report : Clinical characteristics and gene mutation of patients with chronic phase chronic myeloid leukemia (CML) to Imatinib at Cipto Mangunkusumo National Hospital (RSUPN.CM). Indonesian Journal of Cancer;2011: 5(4): 147-151.

Kim H, Kim S, Kim H, Kim Y, Kwak J, Yhim H et al. Comparison of frequency and sensitivity of Bcr-Abl1 kinase domain mutations in Asian and White patients with imatinib resistant chronic phase Chronic Myeloid Leukemia. Clinical Lymphoma & Leukemia. 2018. 18(10): e391-9.

Somnarman, Machsoos BD and Hermanto DH. Comparison of Sokal Score and Hasford Score

against the respons of Imatinib mesylate therapy in patients with Chronic Granulocytic Leukemia in Dr.Saiful Anwar Hospital Malang. Jurnal Penyakit Dalam Indonesia. 2019. 6(4) : p164-172.

Kantarjian HM, Hughes TO, Larson RA, Kim D, Issaragrisil S, Coutre P et al. Long term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase : ENESTnd 10-year analysis. Leukemia. 2021. 35 : 440-453.

Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG et al. Treatment-free remission following nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of the ENESTfreedom trial. Leukemia.2021. 35 : 1344-1355.

Riswan M, Pratama SE, Fuad M, Irawandi. Korelasi Skor Sokal terhadap respons molecular mayor pada penderita chronic myeloid leukemia yang mendapat terapi nilotinib. Jurnal Kedokteran Syah Kuala. 2023. 23(1) : p.47-59.

Sumantri AF, Oehadian A, Wijaya I, Vidyaniati P, Rahmaniati. Therapeutic Responses of Imatinib and Nilotinib among CML patients in Hasan Sadikin Hospital Bandung. Indonesian Journal of Cancer. 2018. 12(3) : p88-94.

Cortes JE, Saglio Final 5-year Study Results of DASSION : The Dasatinib versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. JCO. 2016. 34(20) : 2333-2340.

Ercaliskan A, Erdogan OS, Eskazan AE. Current evidence on the efficacy and savety of generic imatinib in CML and the impact of generic on healthcare costs. Blood advances 2021.5(17)1-10

Malkan UY, Aksu S, Aktimur SH, Atay H, Bektas O, Buyukasik Y et al. Generic imatinib mesylate is an effective as original Glivec in the clinical management of CML. UHOD. 2015. 4(5):215-221

Downloads

Published

2023-11-25

How to Cite

Wardhani, S. O. (2023). Tailored CML Treatment in Indonesia, Let’s See More. Clinical and Research Journal in Internal Medicine, 4(2), 440–443. https://doi.org/10.21776/ub.crjim.2023.004.02.01